We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+30.25%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$12B
AUM Growth
+$2.23B
Cap. Flow
-$2.3B
Cap. Flow %
-19.15%
Top 10 Hldgs %
76.74%
Holding
140
New
18
Increased
23
Reduced
51
Closed
10

Top Buys

Rank Stock Value
1
NVTA
Invitae Corporation
NVTA
+$121M
2
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$106M
3
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$76.4M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$51.5M
5
SGEN
Seagen Inc. Common Stock
SGEN
+$34.6M

Top Sells

Rank Stock Value
1
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$653M
2
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$73M
3
VNDA icon
Vanda Pharmaceuticals
VNDA
+$30.8M
4
PCYC
PHARMACYCLICS INC
PCYC
+$17.3M
5
XOMA
Xoma
XOMA
+$8.13M

Sector Composition

Rank Sector Weight
1 Healthcare 40.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVNR
126
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
– –
-38,513,713
Closed -$653M
AST
127
DELISTED
Asterias Biotherapeutics Inc. Series A
AST
– –
-16,775
Closed -$54K
2 3 4 5
6

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2015 Portfolio in Review

As of Q1 2015, Baker Bros. Advisors held 140 positions worth $12B, up 23% from $9.8B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Baker Bros. Advisors withdrew a net $2.3B in Q1 2015, closing 10 positions and reducing 51 holdings. Its most notable exit was AVANIR PHARMACEUTICALS, INC CL A, an estimated $653M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 40% of assets, down from 42% a quarter earlier.

Against the trend, Baker Bros. Advisors opened a new position in Invitae Corporation worth $110M.

  • Baker Bros. Advisors's largest Q1 2015 buy was Invitae Corporation: 6,554,967 shares worth $110M.
  • Baker Bros. Advisors added most to SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q1 2015, an estimated $106M increase.
  • Baker Bros. Advisors's biggest Q1 2015 reduction was Vanda Pharmaceuticals, cutting an estimated $30.8M.
  • Baker Bros. Advisors fully exited AVANIR PHARMACEUTICALS, INC CL A in Q1 2015, selling an estimated $653M.
  • Baker Bros. Advisors's ten largest holdings make up 77% of its $12B portfolio in Q1 2015.
  • Baker Bros. Advisors opened 18 new positions and closed 10 in Q1 2015.
  • Baker Bros. Advisors's portfolio value rose 23% quarter-over-quarter to $12B.

Based on Baker Bros. Advisors's 13F filing for Q1 2015, filed 15 May 2015.